Howard Lutnick is the U.S. Secretary of Commerce and the former CEO of Cantor Fitzgerald. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site ...

Since ending in correction territory last week, Wall Street has rebounded, and Cantor Fitzgerald believes this rally could extend through to the end of the month. However, despite the potential ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Rocket Pharmaceuticals (NASDAQ:RCKT) with a steady price target of $50.00. Following a webinar with the company’s management ...

THE CENTRAL BANK has fined the Irish branch of investment firm Cantor Fitzgerald €452,790 for failing to report suspicious stock transactions to regulators “on a number of occasions”.

The Irish unit of Cantor Fitzgerald, the US investment group previously run by Donald Trump’s new commerce secretary, has been fined €452,790 by the Central Bank for failing on a number of ...

The Central Bank has fined the Irish unit of US investment group Cantor Fitzgerald €452,790 for failing to report suspicious transactions that may have indicated market abuse. Between March 2017 ...

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating.Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) – Stock analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Protara Therapeutics in a research note issued on Thursday ...

Friday - Summit Therapeutics plc (NASDAQ:SMMT) stock received a new Overweight rating from Cantor Fitzgerald, signaling a positive outlook from the firm. The coverage initiation by Cantor ...

Eric Johnston, chief equity and macro strategist at Cantor Fitzgerald, said he believes stocks are in for a tactical short-term bounce of 3-4% within the next couple of weeks. In an email ...

Global Head of Cantor Fitzgerald Asset Management. "This growth underscores our commitment to creating lasting economic impact and revitalizing neighborhoods across the United States. We are ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Cartesian Therapeutics (NASDAQ:RNAC), currently trading at $15.80, with a steady price target of $22.00. The stock has experienced an ...